15.45
Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten
Arcturus Therapeutics to Attend Upcoming Investor Conferences - Business Wire
What analysts say about Arcturus Therapeutics Holdings Inc. stockRapid growth opportunities - Autocar Professional
What drives Arcturus Therapeutics Holdings Inc. stock priceBreakthrough financial growth - jammulinksnews.com
Arcturus Therapeutics Holdings Inc. Stock Analysis and ForecastUnstoppable profit momentum - Autocar Professional
Is Arcturus Therapeutics Holdings Inc. a good long term investmentAccelerated investment success - Autocar Professional
What makes Arcturus Therapeutics Holdings Inc. stock price move sharplyFree Access to Community - Newser
What drives PLUR stock priceRobust investment performance - jammulinksnews.com
Arcturus Therapeutics Stock Rises After Promising Mid-Stage Data for OTC Deficiency Treatment - MSN
Best Stocks for Aggressive Growth Pro Stock Market SignalsFree Consultation - jammulinksnews.com
What drives KSPI stock priceFree Stock Market Forecast Reports - jammulinksnews.com
RNA Therapeutics and RNA Vaccines Market Industry Report 2025-2035: Investments in RNA Technologies Surge with USD 2.9 Billion Funding - GlobeNewswire Inc.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $54.00 Consensus PT from Analysts - Defense World
Why Arcturus Therapeutics Holdings Inc. stock attracts strong analyst attentionHigh Potential Safe Trades - Newser
How Arcturus Therapeutics Holdings Inc. stock performs during market volatilityRisk Managed Trading Strategy - Newser
Trend Tracker for (ARCT) - news.stocktradersdaily.com
Arcturus Therapeutics (NASDAQ:ARCT) Downgraded by Wall Street Zen to “Sell” - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World
Expert Outlook: Arcturus Therapeutics Through The Eyes Of 5 Analysts - Nasdaq
Arcturus Therapeutics stock rises as Cantor Fitzgerald reiterates Overweight rating - Investing.com
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program - BioSpace
Arcturus Therapeutics stock rises on positive OTC deficiency trial data By Investing.com - Investing.com Australia
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency - Yahoo Finance
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Bank of America Corp DE - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Analysts Offer Predictions for ARCT FY2026 Earnings - Defense World
Two Sigma Investments LP Increases Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
(ARCT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Squarepoint Ops LLC Sells 22,752 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics Holdings Inc (ARCT) Is A Good Stock To Invest In - Stocksregister
Arcturus Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Transcript : Arcturus Therapeutics Holdings Inc.Shareholder/Analyst Call - marketscreener.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Position Increased by Ameriprise Financial Inc. - Defense World
Nuveen Asset Management LLC Sells 10,221 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
BNP Paribas Financial Markets Sells 13,093 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet - sharewise
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):